First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia
March 7 (Reuters) - The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's (6160.HK), opens new tab combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.
BeiGene Announces FDA Accelerated Approval of BRUKINSA
FDA Confirms Paragraph IV Patent Litigation for Zanubrutinib Capsules
BeiGene`s Brukinsa (zanubrutinib) Receives Approval in Europe
China's BeiGene, a global, science-driven biotechnology company, has announced that its anti-cancer drug zanubrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), has been added to Singapore’s Ministry of Health (MoH) Cancer Drug List (CDL) for multiple indications.
BeiGene Receives European Commission Approval for BRUKINSA
The non-late breaking abstracts for next month’s American Society of Hematology meeting were released on Thursday, giving a peek into what will be some of the most heavily scrutinized data in San Diego in early December.
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult Patients with Chronic Lymphocytic Leukemia
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma